Related Experiment Video
Updated: Aug 30, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Cyclooxygenase inhibition in cancer prevention and treatment
William F Anderson1, Asad Umar, Ernest T Hawk
1Gastrointestinal & Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, EPN, Room 2141, 6130 Executive Boulevard, Bethesda, MD 20892-7317, USA.
Abstract:
Several lines of evidence suggest that the cyclooxygenase enzymes (specifically COX-2) might be an important molecular target for the intervention of cancer at both early and late stages of some cancers, providing an opportunity for both cancer prevention and therapy. COX-2 is overexpressed during carcinogenesis, and appears to have a role in both tumour initiation and promotion and is amenable to intervention. This review discusses the importance of COX modulation via non-specific, as well as COX-2 specific COX inhibitors (NSAIDs and COX-2 selective inhibitors [COXIB]). A brief discussion on the pharmacoeconomic considerations of NSAID and COXIB use and safety issues that have recently been the focus of debate, will be presented.
Insights
Cyclooxygenase-2 (COX-2) is a key target for cancer prevention and therapy. Modulating COX-2 with inhibitors like NSAIDs and COXIBs offers therapeutic opportunities, though safety and economic factors require consideration.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cyclooxygenase-2 (COX-2) is overexpressed during cancer development.
- COX-2 plays a role in tumor initiation and promotion.
- Targeting COX-2 presents opportunities for cancer intervention.
Purpose of the Study:
- To review the role of COX-2 in cancer.
- To discuss COX modulation strategies using NSAIDs and COXIBs.
- To examine pharmacoeconomic and safety aspects of COX inhibitors.
Main Methods:
- Literature review of studies on COX-2 and cancer.
- Analysis of non-specific and COX-2 selective inhibitors.
- Discussion of pharmacoeconomic and safety data.
Main Results:
- COX-2 is a viable molecular target for cancer prevention and therapy.
- Non-specific NSAIDs and selective COXIBs are key modulators.
- Safety and economic considerations are crucial for clinical application.
Conclusions:
- COX-2 inhibition is a promising strategy for cancer intervention.
- Careful consideration of NSAID and COXIB use, including safety and cost, is essential.
- Further research into optimal COX-2 targeting is warranted.
More Related Videos
10:01Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Prevention
Some...